Shares of ALNY " Alnylam Pharmaceuticals " will be in focus today after Swiss drug maker Roche Holding AG said Monday it has entered into an alliance with Alnylam Pharmaceuticals Inc. giving it access to the U.S.-based company's research into so-called RNA interference therapy. Shares rose more than 50% in the pre-market.

Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical examples.

Labels: ALNY